Promoter of Eno1 gene

By using Chinese hamster or mouse Eno1 gene promoter and human EF1α promoter or DNA element A7, the exogenous gene expression activity in mammalian cells is improved, the problems of low productivity and high cost of exogenous proteins are solved, and high efficiency is achieved , low-cost production of protein-based drugs.

CN119013400APending Publication Date: 2024-11-22DAIICHI SANKYO CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380032676.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-10-06
Filing Date
2023-04-25
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

In mammalian cultured cells, the productivity of the exogenous gene expression system is low and the cost is high, resulting in high manufacturing costs of protein-based drugs, and it is difficult for the prior art to effectively improve production efficiency and reduce costs.

Method used

The Eno1 gene promoter derived from Chinese hamsters or mice is used to combine human EF1α promoter or DNA element A7 to construct an exogenous gene expression vector, and the expression activity and production of exogenous proteins are improved through gene introduction technology.

Benefits of technology

It significantly increases the production of exogenous proteins, reduces manufacturing costs, and achieves the goal of efficiently producing protein-based drugs in mammalian cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119013400A_ABST
    Figure CN119013400A_ABST
Patent Text Reader

Abstract

Provided is a promoter having high foreign gene expression enhancing activity in host cells such as cultured cells of mammals, and also provided is a polynucleotide which is a promoter derived from a Chinese hamster gene and which can be used as a means for enhancing the production of a foreign protein, which is a proteinaceous drug, by using the promoter. A nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, and SEQ ID NO: 14, or comprising a nucleotide sequence having at least 85% sequence identity with these sequences or a partial sequence of the nucleotide sequence.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a mammalian transformed cell having enhanced transcriptional activity of a foreign protein obtained by using a foreign gene expression vector having a promoter of the Eno1 gene, and a method for producing the foreign protein using the same. Background Art

[0002] The market for protein drugs such as therapeutic proteins and antibody drugs is expanding rapidly due to the development of gene recombination technology. Among them, antibody drugs are actively developed because they have a low risk of causing harmful immune reactions even when administered to the human body and have high specificity.

[0003] As hosts for producing protein drugs represented by antibody drugs, microorganisms, yeast, animal and plant cells, insects, transgenic animals and plants, etc. can be cited. In terms of the physiological activity and antigenicity of protein drugs, correct folding and post-translational modifications such as sugar chain modification are often required. Therefore, microorganisms that cannot perform sugar chain modification and plants with large differences in sugar chain structure are not suitable as hosts. Mammalian cultured cells such as CHO (Chinese Hamster Ovary) cells, which have sugar chain structures similar to those of humans, can perform post-translational modifications, and have no concerns about safety due to the actual large-scale use, have become the mainstream now.

[0004] When using mammalian cultured cells as hosts, compared with microorganisms, there are problems such as low proliferation rate, low productivity, expensive cost (non-patent literature 1). In addition, in order to utilize antibody drugs clinically, a large amount of administration is required, so the deficiency of its production capacity worldwide also becomes a problem. When utilizing mammalian cultured cell expression systems to manufacture protein drugs, the manufacturing cost is high compared with synthetic low-molecular drugs, so the reduction of manufacturing cost is sought by the improvement of each manufacturing process, and the increase of the production volume in the mammalian cultured cell expression system is also an effective method for reducing manufacturing cost (non-patent literature 2,3). Therefore, in order to improve the productivity of foreign proteins in mammalian cultured cells, so far, multiple approaches such as promoters, enhancers, drug screening markers, gene amplification, and culture engineering methods have been tried incorrectly.

[0005] When CHO cells are used as host cells, in the expression of foreign genes, that is, in the production of protein drugs, the human cytomegalovirus major immediate early promoter (hereinafter referred to as CMV promoter) derived from the virus is usually used (non-patent documents 4, 5, 6). In addition, it is known that in CHO cells, the polynucleotide (promoter region) of the upstream region of the transcription start point of EF1α (elongation factor-1alpha) (Patent Document 1, Non-Patent Document 7) and RPL32 and RPS11, which are human ribosomal protein genes, can be used alone or in combination with other heterologous promoters for protein expression (Non-Patent Document 8, Patent Documents 2, 3). In mammalian cells, the promoters of the heat shock protein A5 (Hspa5 / GRP78) gene and the heat shock protein A8 (Hspa8) that increase the productivity of foreign proteins are known (Patent Documents 4, 5).

[0006] Prior art literature

[0007] Patent Literature

[0008] Patent Document 1: Japanese Patent No. 3051411

[0009] Patent Document 2: International Publication No. 2006 / 123097

[0010] Patent Document 3: International Publication No. 2013 / 080934

[0011] Patent Document 4: International Publication No. 2018 / 066492

[0012] Patent Document 5: International Publication No. 2020 / 032153

[0013] Non-patent literature

[0014] Non-patent document 1: Florian M. Wurm., Nat. Biotechnol. 22(11):1393-1398, 2004

[0015] Non-patent document 2: Farid SS., J Chromatogr B Analyt Technol Biomed Life Sci. 848(1):8-18, 2007

[0016] Non-patent document 3: Werner RG. Economic aspects of commercial manufacture of biopharmaceuticals. J Biotechnol. 113(1-3):171-182, 2004

[0017] Non-patent document 4: Durocher Y et al., Curr Opin Biotechnol. 20(6):700-707, 2009

[0018] Non-patent document 5: Boshart M et al., Cell. 41(2):521-530, 1985

[0019] Non-patent document 6: Foecking MK et al., Gene. 45(1): 101-105, 1986 Non-patent document 7: Deer JR. and Allison DS., Biotechnol. Prog. 20: 880-889, 2004

[0020] Non-patent document 8: Hoeksema F. et al., Biotechnology Research International, Volume 2011, Article ID 492875, page 11 Summary of the invention

[0021] Problems to be solved by the invention

[0022] An object of the present invention is to provide a promoter having a high activity of enhancing the expression of a foreign gene in a host cell such as a mammalian cultured cell, and to provide a means for enhancing the production of a foreign protein as a proteinaceous drug using the promoter.

[0023] Means for solving problems

[0024] In order to solve the above-mentioned problems, the present invention provides the following [1]-

[34] .

[0025] [1] a polynucleotide which is a promoter of a gene derived from Chinese hamster,

[0026] The polynucleotide is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13 and SEQ ID NO: 14, or,

[0027] The polynucleotide comprises a nucleotide sequence having at least 85% sequence identity with these sequences or a partial sequence of the nucleotide sequence.

[0028] [2] The polynucleotide of [1], which is selected from SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 12, or

[0029] The polynucleotide comprises a nucleotide sequence having at least 85% sequence identity with these sequences or a partial sequence of the nucleotide sequence.

[0030] [2a] The polynucleotide of [1] or [2], comprising the nucleotide sequence of SEQ ID NO: 18 or a nucleotide sequence having at least 85% sequence identity with the nucleotide sequence.

[0031] [3] The polynucleotide according to [1], comprising a nucleotide sequence having a sequence identity of at least 99% with the nucleotide sequence of SEQ ID NO: 1.

[0032] [4] The polynucleotide according to [1], comprising a nucleotide sequence having a sequence identity of at least 99% with the nucleotide sequence of SEQ ID NO: 3.

[0033] [5] The polynucleotide of [1], comprising a nucleotide sequence having a sequence identity of at least 99% with the nucleotide sequence of SEQ ID NO: 4.

[0034] [6] The polynucleotide of [1], comprising a nucleotide sequence having a sequence identity of at least 99% with the nucleotide sequence of SEQ ID NO: 10.

[0035] [7] The polynucleotide of [1], comprising a nucleotide sequence having a sequence identity of at least 99% with the nucleotide sequence of SEQ ID NO: 11.

[0036] [8] The polynucleotide of [1], comprising a nucleotide sequence having a sequence identity of at least 99% with the nucleotide sequence of SEQ ID NO: 12.

[0037] [9] The polynucleotide of [1], comprising a nucleotide sequence having a sequence identity of at least 99% with the nucleotide sequence of SEQ ID NO: 13.

[0038]

[10] The polynucleotide of [1], comprising a nucleotide sequence having a sequence identity of at least 99% with the nucleotide sequence of SEQ ID NO: 14.

[0039] [10a] A polynucleotide which is a promoter of a gene derived from Chinese hamster, the polynucleotide comprising the nucleotide sequence of SEQ ID NO: 18 or a nucleotide sequence having a sequence identity of at least 85% with the sequence.

[0040] [10b] The polynucleotide of [10a], which is selected from SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12 and SEQ ID NO: 13, or

[0041] The polynucleotide comprises a nucleotide sequence having at least 85% sequence identity with these sequences or a partial sequence of the nucleotide sequence.

[0042]

[11] a polynucleotide which is a promoter of a gene derived from mouse,

[0043] The polynucleotide is selected from SEQ ID NO: 2, SEQ ID NO: 17 and SEQ ID NO: 16, or,

[0044] The polynucleotide comprises a nucleotide sequence having at least 85% sequence identity with these sequences or a partial sequence of the nucleotide sequence.

[0045] [11a] The polynucleotide of

[11] , which comprises a nucleotide sequence having a sequence identity of at least 85% with the nucleotide sequence of SEQ ID NO: 18.

[0046]

[12] The polynucleotide of

[11] , comprising a nucleotide sequence having a sequence identity of at least 99% with the nucleotide sequence of SEQ ID NO: 2.

[0047]

[13] The polynucleotide of

[11] , comprising a nucleotide sequence having a sequence identity of at least 99% with the nucleotide sequence of SEQ ID NO: 17.

[0048]

[14] The polynucleotide of

[11] , comprising a nucleotide sequence having a sequence identity of at least 99% with the nucleotide sequence of SEQ ID NO: 16.

[0049] [14a] A polynucleotide which is a promoter of a gene derived from a mouse, the polynucleotide comprising a nucleotide sequence having a sequence identity of at least 85% with the nucleotide sequence of SEQ ID NO: 18.

[0050] [14b] The polynucleotide of [14a], which is selected from SEQ ID NO: 2, SEQ ID NO: 17 and SEQ ID NO: 16, or

[0051] The polynucleotide comprises a nucleotide sequence having at least 85% sequence identity with these sequences or a partial sequence of the nucleotide sequence.

[0052]

[15] A polynucleotide having promoter activity, wherein the polynucleotide comprises a nucleotide sequence having a sequence identity of 90% or more to the nucleotide sequence of sequence number 1, sequence number 3, sequence number 4, sequence number 10, sequence number 11, sequence number 12, sequence number 13, sequence number 14, sequence number 2, sequence number 17 or sequence number 16 of [1] or

[11] , or a partial sequence of the nucleotide sequence.

[0053]

[16] A polynucleotide having promoter activity, wherein the polynucleotide comprises a nucleotide sequence having a sequence identity of 95% or more to the nucleotide sequence of sequence number 1, sequence number 3, sequence number 4, sequence number 10, sequence number 11, sequence number 12, sequence number 13, sequence number 14, sequence number 2, sequence number 17 or sequence number 16 of [1] or

[11] , or a partial sequence of the nucleotide sequence.

[0054]

[17] A polynucleotide having promoter activity, which is a polynucleotide that hybridizes under stringent conditions with a polynucleotide comprising a nucleotide sequence complementary to the nucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 2, SEQ ID NO: 17 or SEQ ID NO: 16 of [1] or

[11] .

[0055] [17a] A polynucleotide as described in any one of [1] to

[17] , wherein the length is 1 kbp to 10 kbp, 2 kbp to 6 kbp, 2.6 kbp to 5 kbp, 2.7 kbp to 4.5 kbp, or 2.8 kbp to 4 kbp.

[0056]

[18] A polynucleotide comprising an exogenous gene and the polynucleotide of any one of [1] to

[17] and [17a].

[0057]

[19] A foreign gene expression unit comprising a foreign gene and the polynucleotide of any one of [1]-

[18] and [17a].

[0058] [19a] The exogenous gene expression unit of

[19] , further comprising a transcription terminator region.

[0059]

[20] The exogenous gene expression unit of

[19] or [19a], wherein the exogenous gene is a gene encoding a protein.

[0060]

[21] The exogenous gene expression unit of

[20] , wherein the exogenous gene is a gene encoding a heteromultimeric protein.

[0061]

[22] The exogenous gene expression unit of

[21] , wherein the exogenous gene is a gene encoding an antibody or an antigen-binding fragment thereof.

[0062]

[23] A foreign gene expression vector comprising the foreign gene expression unit of any one of

[19] -

[22] and [19a].

[0063]

[24] A foreign gene expression vector comprising:

[0064] The exogenous gene expression unit of any one of

[19] to

[22] and [19a]; and

[0065] A polynucleotide selected from any one or more of the following (a) to (e),

[0066] (a) the nucleotide sequence of SEQ ID NO: 5 or a partial sequence thereof;

[0067] (b) the nucleotide sequence of SEQ ID NO: 6 or a partial sequence thereof;

[0068] (c) the nucleotide sequence of SEQ ID NO: 7 or a partial sequence thereof;

[0069] (d) a polynucleotide comprising a nucleotide sequence having a sequence identity of 80% or more to the nucleotide sequence of SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 7, or a partial sequence of the nucleotide sequence, wherein the polynucleotide has an activity of enhancing the expression of a foreign gene;

[0070] (e) A polynucleotide comprising a nucleotide sequence having a sequence identity of 85% or more to the nucleotide sequence of SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 7, or a partial sequence of the nucleotide sequence, wherein the polynucleotide has an activity of enhancing the expression of a foreign gene.

[0071] [24a] A foreign gene expression vector comprising:

[0072] The exogenous gene expression unit of any one of

[19] to

[22] and [19a]; and

[0073] The polynucleotide of (b) or (d) below,

[0074] (b) the nucleotide sequence of SEQ ID NO: 6 or a partial sequence thereof;

[0075] (d) A polynucleotide comprising a nucleotide sequence having a sequence identity of 80% or more to the nucleotide sequence of SEQ ID NO: 6 or a partial sequence of the nucleotide sequence, wherein the polynucleotide has an activity of enhancing the expression of a foreign gene.

[0076]

[25] A transformed cell into which the foreign gene expression vector described in

[23] ,

[24] or [24a] has been introduced.

[0077]

[26] The transformed cell according to

[24] , which is a cultured cell derived from a mammal.

[0078]

[27] The transformed cell according to

[25] , which is a COS-1 cell, a 293 cell or a CHO cell.

[0079]

[28] A method for producing a protein, characterized in that the transformed cell according to any one of

[25] to

[27] is cultured and a protein derived from a foreign gene is obtained from the culture.

[0080]

[29] The production method according to

[28] , wherein the protein derived from the foreign gene is a monomeric protein or a multimeric protein.

[0081]

[30] The production method according to

[29] , wherein the multimeric protein is a heteromultimeric protein.

[0082]

[31] The production method according to

[30] , wherein the heteromultimeric protein is an antibody protein.

[0083] [31a] The production method according to any one of

[28] to

[31] , wherein the culture of the transformed cells is a fed-batch culture.

[0084] [31b] ​​The method of any one of

[28] -

[31] and [31a], wherein the transformed cells are cultured for more than 6 days.

[0085]

[32] Use of the polynucleotide of any one of [1] to

[18] for expressing a foreign gene in a transformed cell.

[0086]

[33] Use of the exogenous gene expression vector of

[23] or

[24] for the purpose of expressing the exogenous gene in transformed cells.

[0087]

[34] A method for producing transformed cells expressing foreign genes by introducing the foreign gene vector of

[23] ,

[24] or [24a].

[0088] Effects of the Invention

[0089] According to the present invention, there are provided a promoter having a high activity of enhancing the expression of a foreign gene in a host cell such as a mammalian cultured cell, and a means for enhancing the production of a foreign protein serving as a proteinaceous drug using the promoter. BRIEF DESCRIPTION OF THE DRAWINGS

[0090] [ Figure 1] is a schematic diagram of the humanized antibody gene Y expression vectors pDSLH3.1-Eno1-Y and pDSLH3.1-hEF1α-Y, which use promoters derived from the Eno1 gene or the human EF1α gene as promoters of the antibody H chain (HC) and L chain (LC) genes.

[0091] [ Figure 2-A ] is a graph comparing the production of antibodies expressed using the Chinese hamster-derived Eno1 gene promoter and the human EF1α gene promoter by fed-batch culture using a stable pool of cells expressing humanized antibody Y. Figure 2-A The vertical axis represents the number of viable cells on each sampling day. hEF1α represents the human EF1α gene promoter, and Eno1 represents the Eno1 gene promoter from Chinese hamsters ( Figure 2-B The same also applies to ).

[0092] [ Figure 2-B ] is a graph comparing the production of antibodies expressed using the Chinese hamster-derived Eno1 gene promoter and the human EF1α gene promoter by fed-batch culture using a stable cell pool expressing humanized antibody Y. Figure 2-B The vertical axis represents the production volume on each sampling day.

[0093] [ Figure 3 ] is a graph comparing the expression of firefly luciferase transiently expressed using a region about 5.0 kbp to 2.5 kbp upstream of the start codon of the Eno1 gene derived from Chinese hamster as a promoter based on each chain length. The vertical axis represents the value obtained by dividing the luminescence of the firefly luciferase on pGL4.10 by the luminescence of the sea renilla luciferase on pGL4.74. In the figure, the regions from the nucleotide immediately before the nucleotide sequence corresponding to the start codon sequence of the Eno1 gene derived from Chinese hamster to about 5.0 kbp upstream (SEQ ID NO: 10), to about 4.5 kbp upstream (SEQ ID NO: 11), to about 4.0 kbp upstream (SEQ ID NO: 4), to about 3.5 kbp upstream (SEQ ID NO: 12), to about 3.0 kbp upstream (SEQ ID NO: 1), to about 2.8 kbp upstream (SEQ ID NO: 3), to about 2.7 kbp upstream (SEQ ID NO: 13), to about 2.6 kbp upstream (SEQ ID NO: 14), and to about 2.5 kbp upstream (SEQ ID NO: 15) are respectively represented as Eno1 5k, Eno1 4.5k, Eno1 4k, Eno1 3.5k, Eno1 3.0k, Eno1 2.8k, Eno1 2.7k, Eno1 2.6k, and Eno1 2.5k.

[0094] [ Figure 4-A ] is a graph comparing the antibody production by fed-batch culture of a stable cell pool expressing humanized antibody Y produced using Eno1 gene promoters derived from various biological species. Eno1 and mEno1 represent the results of the Eno1 gene promoter derived from Chinese hamster and mouse, respectively. Figure 4-A The vertical axis represents the number of viable cells on each sampling day. In the figure, the regions from the nucleotide immediately before the nucleotide sequence corresponding to the start codon sequence of the Eno1 gene derived from the Chinese hamster to about 4.0 kbp upstream (sequence number 4), to about 3.5 kbp upstream (sequence number 12), to about 3.0 kbp upstream (sequence number 1), and to about 2.8 kbp upstream (sequence number 3) are respectively recorded as Eno1 4k, Eno1 3.5k, Eno1 3k, and Eno1 2.8k. The regions from the nucleotide immediately before the nucleotide sequence corresponding to the start codon sequence of the Eno1 gene derived from the mouse to about 4.0 kbp upstream (sequence number 16), to about 3.5 kbp upstream (sequence number 17), and to about 3.0 kbp upstream (sequence number 2) are respectively recorded as mEno1 4k, mEno1 3.5k, mEno1 3k ( Figure 4-B The same also applies to ).

[0095] [ Figure 4-B ] is a graph comparing the antibody production by fed-batch culture of a stable cell pool expressing humanized antibody Y produced using Eno1 gene promoters derived from various biological species. Eno1 and mEno1 represent the results of the Eno1 gene promoter derived from Chinese hamster and mouse, respectively. Figure 4-B The vertical axis represents the production volume on each sampling day.

[0096] [ Figure 5-A ] is a graph comparing the antibody production by fed-batch culture of a stable cell pool expressing humanized antibody Y produced by combining Eno1 gene promoters derived from various species with DNA element A7. Eno1 and mEno1 represent the results of the Eno1 gene promoter derived from Chinese hamster and the Eno1 gene promoter derived from mouse, respectively. Figure 5-A The vertical axis represents the number of viable cells on each sampling day. Figure 4-A Similarly, when combined with DNA element A7, it is recorded as A7(+), and when there is no A7, it is recorded as A7(-) ( Figure 5-B Same as above).

[0097] [ Figure 5-B] is a graph comparing the antibody production amounts by fed-batch culture of a stable cell pool expressing humanized antibody Y produced by combining the Eno1 gene promoter derived from various biological species with the DNA element A7. Figure 5-B The vertical axis represents the production volume on each sampling day.

[0098] [Figure 6] Sequence Listing DETAILED DESCRIPTION

[0099] Hereinafter, a preferred mode for carrying out the present invention will be described. It should be noted that the embodiment described below is an example of a representative embodiment of the present invention, and the scope of the present invention is not to be narrowly interpreted based on the embodiment.

[0100] In this specification, "gene" refers to a part that is transcribed into mRNA and translated into protein, and includes not only DNA but also its mRNA, cDNA and its RNA.

[0101] In this specification, "polynucleotide" is used with the same meaning as nucleic acid, and also includes DNA, RNA, probes, oligonucleotides and primers.

[0102] In this specification, "polypeptide" and "protein" are used without distinction.

[0103] In this specification, "gene expression" refers to a phenomenon in which a gene is transcribed into mRNA and / or a phenomenon in which the mRNA is translated into protein.

[0104] In the present specification, "foreign gene" refers to a gene artificially introduced into a host cell.

[0105] In the present specification, "foreign protein" refers to a protein encoded by a foreign gene.

[0106] In the present specification, the "gene expression unit" refers to a polynucleotide having at least a promoter region, a foreign gene, and a transcription terminator region (poly A tailing signal) in the reading frame direction of transcription.

[0107] In this specification, "promoter" refers to a region to which a transcription factor associated with the start of transcription from DNA to RNA binds. In this specification, it is also referred to as a "promoter region". As a promoter, for example, a polynucleotide from the nucleotide about 3 kbp upstream of the start codon to the nucleotide immediately before the nucleotide sequence corresponding to the start codon can be exemplified, and may include a 5'UTR and an intron.

[0108] In this specification, "promoter activity" refers to the activity of a transcription factor binding to a promoter to initiate transcription and produce a protein encoded by a gene, and the activity of a protein encoded by a reporter gene such as firefly luciferase can be used as an indicator for testing.

[0109] In the present specification, "having promoter activity" means that antibody expression can be confirmed under the same conditions as the evaluation of promoter activity using the antibody expression amount in the fed-batch culture described later (Example 2) as an indicator, or that firefly luciferase shows activity under the same conditions as the method described later (Example 3).

[0110] In the present specification, the "DNA element" refers to a polynucleotide having an activity of enhancing the expression of a foreign gene when arranged in the vicinity of a gene expression unit or when arranged on a foreign gene expression vector containing a gene expression unit.

[0111] In the present specification, "antibody antigen-binding fragment" refers to a partial fragment of an antibody having antigen-binding activity, including Fab, F(ab')2, etc., but is not limited to these molecules as long as they have the ability to bind to an antigen.

[0112] In this specification, "sequence identity" refers to the relationship between sequences of more than two nucleotide sequences or amino acid sequences determined by comparison of sequences as known in the field. In this field, "sequence identity" refers to the level of sequence correlation between nucleic acid molecules or polypeptides when determined based on the consistency between more than two nucleotide sequences or more than two amino acid sequences in a row according to the circumstances." sequence identity" can be evaluated by the following method: calculate the smaller sequence among more than two sequences, and the same percentage of the gap alignment (if present) addressed by a specific mathematical model or computer program (i.e., "algorithm"). Specifically, it can be evaluated by using software such as ClustalW2 provided by the European Molecular Biology Laboratory-European Center for Bioinformatics (EMBL-EBI), as long as it is the software used by those skilled in the art, it is not limited thereto.

[0113] In this specification, "hybridization under stringent conditions" refers to the conditions under which so-called specific hybridization is formed and non-specific hybridization is not formed. For example, the complementary chain of a nucleic acid containing a nucleotide sequence with a sequence identity of 80% or more, preferably 90% or more, more preferably 95% or more, and most preferably 99% or more can be cited for hybridization, and the complementary chain of a nucleic acid containing a nucleotide sequence with a lower sequence identity than it is not hybridized. More specifically, it refers to hybridization under the following conditions or conditions equivalent thereto: hybridization at 68°C in a commercially available hybridization solution ExpressHybHybridization Solution (manufactured by Clontech), or using a filter fixed with DNA, hybridization at 68°C in the presence of 0.7 to 1.0M NaCl, and then washing at 68°C using a 0.1 to 2 times concentration SSC solution (1 times concentration SSC refers to containing 150mM NaCl, 15mM sodium citrate).

[0114] In this specification, "about" means a value that varies within 10%, 8%, 6%, 5%, 4%, 3%, 2% or 1% relative to a reference value. Preferably, the term "about" means a range of 10%, 5% or 1% relative to a reference value.

[0115] 1. Promoter for enhancing the expression of foreign genes

[0116] The promoter used for enhancing the expression of a foreign gene of the present invention (hereinafter also referred to as "the promoter of the present invention") is the promoter of the α-enolase (hereinafter referred to as "Eno1") gene.

[0117] The origin of the promoter of the Eno1 gene is not particularly limited, and may be derived from mammals, for example, promoters of the Eno1 gene derived from Chinese hamsters, humans, mice, etc. The promoter of the present invention is preferably a promoter of the Eno1 gene derived from rodents, more preferably a promoter of the Eno1 gene derived from Chinese hamsters or mice, and even more preferably a promoter of the Eno1 gene derived from Chinese hamsters.

[0118] Examples of the promoter derived from the Chinese hamster Eno1 gene include a sequence comprising nucleotides from 2.0 kbp, 2.5 kbp, 2.6 kbp, 2.7 kbp, 2.8 kbp, 3.0 kbp, 3.5 kbp, 4.0 kbp, 4.5 kbp, 5.0 kbp, 5.5 kbp, and 6.0 kbp upstream of the start codon of the Eno1 gene to the nucleotide immediately before the nucleotide sequence corresponding to the start codon.

[0119] More specifically, examples of the promoter derived from the Chinese hamster Eno1 gene include polynucleotides of SEQ ID NOs: 1, 3, 4, 10, 11, 12, 13, and 14.

[0120] The nucleotide sequence of SEQ ID NO: 1 is a sequence consisting of a nucleotide approximately 3.0 kbp upstream of the start codon of the Chinese hamster Eno1 gene to the nucleotide immediately before the nucleotide sequence corresponding to the start codon.

[0121] The nucleotide sequence of SEQ ID NO: 3 is a sequence consisting of the nucleotides from about 2.8 kbp upstream of the start codon of the Chinese hamster Eno1 gene to the nucleotides immediately before the nucleotide sequence corresponding to the start codon.

[0122] The nucleotide sequence of SEQ ID NO: 4 is a sequence consisting of the nucleotides from about 4.0 kbp upstream of the start codon of the Chinese hamster Eno1 gene to the nucleotides immediately before the nucleotide sequence corresponding to the start codon.

[0123] The nucleotide sequence of SEQ ID NO: 10 is a sequence consisting of a nucleotide approximately 5.0 kbp upstream of the start codon of the Chinese hamster Eno1 gene to the nucleotide immediately before the nucleotide sequence corresponding to the start codon.

[0124] The nucleotide sequence of SEQ ID NO: 11 is a sequence consisting of the nucleotides from about 4.5 kbp upstream of the start codon of the Chinese hamster Eno1 gene to the nucleotides immediately before the nucleotide sequence corresponding to the start codon.

[0125] The nucleotide sequence of SEQ ID NO: 12 is a sequence consisting of the nucleotides approximately 3.5 kbp upstream of the start codon of the Chinese hamster Eno1 gene to the nucleotides immediately before the nucleotide sequence corresponding to the start codon.

[0126] The nucleotide sequence of SEQ ID NO: 13 is a sequence consisting of the nucleotides from about 2.7 kbp upstream of the start codon of the Chinese hamster Eno1 gene to the nucleotides immediately before the nucleotide sequence corresponding to the start codon.

[0127] The nucleotide sequence of SEQ ID NO: 14 is a sequence consisting of the nucleotides from about 2.6 kbp upstream of the start codon of the Chinese hamster Eno1 gene to the nucleotides immediately before the nucleotide sequence corresponding to the start codon.

[0128] For the promoter of the Eno1 gene, in order to achieve its excellent transcriptional activity, it can be set to a length of about 2.8 kbp upstream of the start codon sequence from the nucleotide immediately before the nucleotide sequence corresponding to the start codon sequence, or a longer region than that. Therefore, from the viewpoint of excellent promoter activity, the promoter of the Eno1 gene derived from Chinese hamster is preferably a polynucleotide of sequence numbers 1, 3, 4, 10, 11, and 12. The promoter of the Eno1 gene derived from Chinese hamster can be more preferably a polynucleotide of sequence numbers 1, 3, 4, and 12, and further preferably a polynucleotide of sequence numbers 1 and 3.

[0129] Examples of the mouse-derived Eno1 gene promoter include sequences including nucleotides from 2.0 kbp, 2.5 kbp, 3.0 kbp, 3.5 kbp, 4.0 kbp, 4.5 kbp, 5.0 kbp, 5.5 kbp, and 6.0 kbp upstream of the start codon of the Eno1 gene to nucleotides immediately before the nucleotide sequence corresponding to the start codon.

[0130] More specifically, the polynucleotides of SEQ ID NOs: 2, 17, and 16 are exemplified as the mouse-derived Eno1 gene promoter.

[0131] The nucleotide sequence of SEQ ID NO: 2 is a sequence consisting of a nucleotide approximately 3.0 kbp upstream of the start codon of the mouse-derived Eno1 gene to the nucleotide immediately before the nucleotide sequence corresponding to the start codon.

[0132] The nucleotide sequence of SEQ ID NO: 17 is a sequence consisting of a nucleotide approximately 3.5 kbp upstream of the start codon of the mouse-derived Eno1 gene to the nucleotide immediately before the nucleotide sequence corresponding to the start codon.

[0133] The nucleotide sequence of SEQ ID NO: 16 is a sequence consisting of a nucleotide approximately 4.0 kbp upstream of the start codon of the mouse-derived Eno1 gene to the nucleotide immediately before the nucleotide sequence corresponding to the start codon.

[0134] In addition, the promoter of the present invention may be a polynucleotide comprising a nucleotide sequence or a partial sequence of the nucleotide sequence having a sequence identity of 80% or more, preferably 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, more preferably 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, further preferably 95% or more, 96% or more, 97% or more, 98% or more, and most preferably 99% or more, or 100% with respect to the nucleotide sequence of any one of SEQ ID NOs: 1, 2, 17, 3, 4, 10, 11, 12, 13, 14, and 16, and having promoter activity.

[0135] The partial sequence may be a fragment having a length of 80% or more, preferably 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, more preferably 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, further preferably 95% or more, 96% or more, 97% or more, 98% or more, and most preferably 99% or more, or 100% of the full length of the nucleotide sequence of any one of SEQ ID NOs: 1, 2, 17, 3, 4, 10, 11, 12, 13, 14, and 16. The partial sequence may be a fragment on the 5' side (upstream) or 3' side (downstream) of the full length, or a fragment obtained by connecting a plurality of regions in the full length.

[0136] The promoter of the present invention can be a polynucleotide that hybridizes under stringent conditions with a polynucleotide comprising a nucleotide sequence complementary to a polynucleotide comprising a nucleotide sequence of any one of sequence numbers 1, 2, 17, 3, 4, 10, 11, 12, 13, 14, and 16, and has promoter activity.

[0137] The promoter of the present invention preferably comprises the nucleotide sequence of sequence number 18 or a nucleotide sequence having at least 85% sequence identity with the sequence, more preferably comprises a sequence having 90% or more, 91% or more, 92% or more, 93% or more, or 94% or more identity, further preferably comprises a sequence having 95% or more, 96% or more, 97% or more, or 98% or more identity, particularly preferably comprises a sequence having 99% or more identity, and most preferably comprises a sequence having 100% identity.

[0138] In particular, the Eno1 promoter derived from Chinese hamster preferably comprises the nucleotide sequence of sequence number 18 or a nucleotide sequence having at least 85% sequence identity with the sequence, more preferably comprises a sequence having 90% or more, 91% or more, 92% or more, 93% or more, or 94% or more identity, further preferably comprises a sequence having 95% or more, 96% or more, 97% or more, or 98% or more identity, particularly preferably comprises a sequence having 99% or more identity, and most preferably comprises a sequence having 100% identity.

[0139] The length of the promoter of the present invention is not particularly limited as long as it is 1 kbp to 10 kbp, but is preferably 2 kbp to 6 kbp, more preferably 2.6 kbp to 5 kbp, further preferably 2.7 kbp to 4.5 kbp, particularly preferably 2.8 kbp to 4 kbp, and typically can be about 3 kbp. Among the promoter lengths that fully have the performance of a promoter, a short promoter is more likely to exert its effect from the aspect of gene introduction efficiency.

[0140] The promoter of the present invention may be a polynucleotide variant of a nucleotide sequence comprising one or more nucleotides deleted, substituted and / or added, preferably 1 to 300, more preferably 1 to 200, further preferably 1 to 100, and particularly preferably 1 to 30 nucleotides in the nucleotide sequence of any one of sequence numbers 1, 2, 17, 3, 4, 10, 11, 12, 13, 14, and 16, and may be a polynucleotide having promoter activity.

[0141] The introduction of the changes (deletions, substitutions and / or additions) of the aforementioned nucleotide sequences can be carried out by methods known in the art such as the Kunkel method or the Gapped duplex method, or by methods in accordance therewith, for example, a mutation introduction kit using a site-specific mutation introduction method (e.g., Mutant-K (manufactured by Takara Bio) or Mutant-G (manufactured by Takara Bio)), Takara Bio's LA PCR in vitro Mutagenesis series kits, etc. Such polynucleotide variants can also be used as the promoter of the present invention.

[0142] The activity of the promoter of the present invention in promoting the expression of a foreign gene can be examined using the activity of a protein encoded by a reporter gene such as firefly luciferase or the amount of antibody produced in a fed-batch culture as an indicator.

[0143] When the activity of the protein encoded by the reporter gene of a vector comprising the promoter of the present invention (for example, the luminescence amount of firefly luciferase) is 1 times or more, preferably 20 times or more, more preferably 30 times or more, further preferably 40 times or more, further more preferably 45 times or more, and particularly preferably 50 times or more as compared to the activity of the protein encoded by the reporter gene of a control vector (for example, the luminescence amount of Renilla luciferase), it can be judged that the promoter has the activity of promoting the expression of exogenous genes.

[0144] When the situation of using the human EF1α promoter is compared with the situation of using the promoter of the present invention, the antibody production amount in the fed-batch culture increases to the same or more, preferably 1.2 times or more, more preferably 1.3 times or more, further preferably 1.5 times or more, particularly preferably 1.8 times, 1.9 times or 2.0 times or more, it can be judged that the promoter has the activity of promoting the expression of foreign genes. Even based on the promotion of more than 1.2 times, it is expected that the culture scale of cells will be reduced, the culture time and the purification process will be shortened, and as a result, the increase in yield and the reduction in culture cost can be achieved. If the yield is increased, the foreign protein as a medicine can be stably supplied. In addition, if the culture cost is reduced, the cost of the foreign protein as a medicine is reduced.

[0145] 2. Foreign gene expression unit

[0146] The exogenous gene expression unit of the present invention (hereinafter also referred to as "the gene expression unit of the present invention") has at least the promoter of the present invention described in 1. above, the exogenous gene and the transcription terminator region (polyA tailing signal) in the direction of the transcription reading frame.

[0147] The polyA tailing (polyadenylation) sequence may be any sequence as long as it has an activity of causing transcription termination from a promoter, and may be a sequence of a gene that is the same as or different from the gene of the promoter.

[0148] 3. DNA elements for enhancing the expression of foreign genes

[0149] By using a DNA element in combination with the gene expression unit of the present invention described in 2. above, the expression of a foreign gene can be further enhanced. The DNA element used in combination can be obtained by using the interaction with acetylated histone H3 as an index. It is generally believed that the acetylation of histones (H3, H4) is related to the activation of transcription, and there are mainly two hypotheses. That is, the theory that the charge is neutralized by acetylation of the histone tail, and the binding between DNA and histone becomes loose, which is related to the change of the three-dimensional structure of the nucleosome (Mellor J. (2006) Dynamic nucleosomes and gene transcription. Trends Genet. 22 (6): 320-329); and the hypothesis related to the recruitment of various transcription factors (Nakatani Y. (2001) Histone acetylases-versatile players. Genes Cells. 6 (2): 79-86). In either hypothesis, there is a high possibility that histone acetylation is associated with transcriptional activation, and DNA elements that interact with acetylated histone H3 can be enriched by chromatin immunoprecipitation (ChIP) using an anti-acetylated histone H3 antibody.

[0150] Examples of DNA elements used in combination with the promoter of the present invention for enhancing the expression of foreign genes include A2, A7, and A18. The DNA element is preferably A7.

[0151] A2 is located at 80966429 to 80974878 of human chromosome 15 and is a polynucleotide of 8450 bp with an AT content of 62.2%. The nucleotide sequence of A2 is shown in SEQ ID NO: 5 in the sequence listing.

[0152] A7 is located at 88992123 to 89000542 of human chromosome 11 and is a polynucleotide of 8420 bp with an AT content of 64.52%. The nucleotide sequence of A7 is shown in SEQ ID NO: 6 in the sequence listing.

[0153] A18 is located at 111275976 to 111284450 on human chromosome 4 and is a polynucleotide of 8475 bp with an AT content of 62.54%. The nucleotide sequence of A18 is shown in SEQ ID NO: 7 in the sequence listing.

[0154] The activity of promoting the expression of a foreign gene possessed by the DNA element used in combination with the promoter of the present invention can be examined using the activity of a protein encoded by a reporter gene such as secretory alkaline phosphatase (SEAP) as an indicator.

[0155] When used in combination with the promoter of the present invention, any one of the aforementioned DNA elements may be used alone, or two or more copies of one of the DNA elements may be used. Alternatively, two or more DNA elements may be used in combination.

[0156] The DNA element used in the present invention may be a nucleotide sequence having a sequence identity of 80% or more, preferably 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, further preferably 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, more preferably 95% or more, 96% or more, 97% or more, 98% or more, most preferably 99% or more, or 100% with respect to the nucleotide sequence of any one of SEQ ID NOs: 5 to 7, and having an activity of enhancing the expression of a foreign gene.

[0157] The DNA element used in the present invention may be a polynucleotide variant comprising a nucleotide sequence in which one or more, preferably 1 to 1000 or 1 to 500, more preferably 1 to 100 or 1 to 50, further preferably 1 to 10 or 1 to 5, particularly preferably 4, 3, 2 or 1 nucleotides are deleted, substituted and / or added to the nucleotide sequence of any one of SEQ ID NOs: 5 to 7, and is a polynucleotide having an activity of enhancing the expression of a foreign gene.

[0158] The introduction of the change (deletion, substitution and / or addition) of the aforementioned polynucleotide can be carried out by a method known in the art such as the Kunkel method or the Gapped duplex method, or by a method according to them, for example, a mutation introduction kit using a site-specific mutation introduction method can be used, for example, Mutant-K (manufactured by Takara Bio) or Mutant-G (manufactured by Takara Bio), LA PCR in vitro Mutagenesis series kits of Takara Bio, etc. Such mutant polynucleotides can also be used as DNA elements of the present invention.

[0159] The DNA element used in the present invention can use a partial sequence comprising at least 3000 or at least 2000 consecutive nucleotides in the polynucleotide sequence described in any one of SEQ ID NOs: 5 to 7. Such a partial sequence may be, for example, a sequence described in International Publication No. 2012 / 005378, and partial sequences of A2 include, for example, A2-1 to A2-17, partial sequences of A7 include, for example, A7-1 to A7-18, and partial sequences of A18 include, for example, A18-1 to A18-4.

[0160] In the present invention, any one of the partial sequences of the aforementioned DNA elements can be used alone, or one of the partial fragments of more than 2 copies can be used. Alternatively, more than two partial fragments can be used in combination. In addition, the full-length sequence and the partial sequence of each DNA element can also be used in combination. In this combination, the partial sequence can be derived from the DNA element of the full-length sequence constituting the combination, or it can be derived from the DNA element of different full-length sequences.

[0161] 4. Acquisition of polynucleotides

[0162] In the present invention, the polynucleotide containing the exogenous gene (which encodes the exogenous protein that becomes the object of hyperproduction described later) can be obtained by the common method shown below. For example, the cDNA library derived from the cells and tissues expressing the exogenous gene can be separated by screening using a DNA probe synthesized based on the gene fragment. The preparation of mRNA can be carried out using the method commonly used in this technical field. For example, the above-mentioned cells or tissues are treated with guanidine reagent, phenol reagent, etc. to obtain total RNA, and then, by using an affinity column method such as PolyU-agarose gel with oligo (dT) cellulose column, agarose gel 2B as a carrier, or by a batch method, Poly (A) + RNA (mRNA) is obtained. Then, Poly (A) + RNA can be further classified by sucrose density gradient centrifugation, etc. Next, the obtained mRNA is used as a template, single-stranded cDNA is synthesized using oligo dT primer and reverse transcriptase, and double-stranded cDNA is synthesized from the single-stranded cDNA using DNA synthase I, DNA ligase and RNaseH, etc. After the synthesized double-stranded cDNA is smoothed by T4 DNA synthetase, it is connected to a linker (e.g., EcoRI linker), phosphorylated, etc., and then incorporated into a λ phage such as λgt11 for in vivo packaging to prepare a cDNA library. In addition to λ phage, a plasmid vector can also be used to prepare a cDNA library. Then, a strain (positive clone) having the target DNA can be selected from the cDNA library.

[0163] In addition, when isolating a polynucleotide containing the aforementioned promoter and terminator region for protein production from genomic DNA, or a polynucleotide containing the aforementioned DNA element or exogenous gene, the polynucleotide can be extracted from a cell line of an organism as a collection source and screened for polynucleotides according to a common method (Molecular Cloning (1989), Methods in Enzymology 194 (1991)). Extraction of genomic DNA can be performed according to, for example, the method of Cryer et al. (Methods in Cell Biology, 12, 39-44 (1975)) and the method of P. Philippsen et al. (Methods Enzymol., 194, 169-182 (1991)).

[0164] Acquisition of a polynucleotide containing a promoter, DNA element or exogenous gene as a target can also be performed by, for example, PCR method (PCR Technology. Henry A. Erlich, Atockton press (1989)). In the amplification of a polynucleotide using the PCR method, a 20-30mer synthetic single-stranded DNA is used as a primer and a genomic DNA is used as a template. The amplified gene is used after confirming the polynucleotide sequence. As a template for PCR, a genomic DNA library such as a bacterial artificial chromosome (BAC) can be used.

[0165] On the other hand, the acquisition of polynucleotides containing foreign genes of unknown sequences can be carried out by the following methods: (a) preparing a gene library by conventional methods; (b) selecting the desired polynucleotide from the prepared gene library and amplifying the polynucleotide. The gene library can be prepared by the following method: using a suitable restriction endonuclease to partially digest the chromosomal DNA obtained by conventional methods from the cell strain of the organism as the collection source to fragment, connecting the obtained fragments to a suitable vector, and introducing the vector into a suitable host. In addition, it can also be prepared by the following method: extracting mRNA from the cell, synthesizing cDNA from it, connecting it to a suitable vector, and introducing the vector into a suitable host. As the vector used at this time, a plasmid known as a vector generally known for preparing a gene library can be used, and a phage vector or cosmid can also be widely used. The host for transformation or transduction can be a host corresponding to the type of the aforementioned vector. As for the selection of polynucleotides containing foreign genes, from the aforementioned gene library, colony hybridization method, plaque hybridization method, etc. using a labeled probe containing a unique sequence in the foreign gene are used.

[0166] In addition, the polynucleotide containing the foreign gene can also be chemically synthesized. For example, the gene can be synthesized by the following methods: a method of preparing two pairs of complementary oligonucleotides and annealing them; a method of connecting multiple annealed DNAs by DNA ligase; or a method of preparing multiple partially complementary oligonucleotides and filling in the gaps by PCR.

[0167] The polynucleotide sequence can be determined by a common method, such as the dideoxy method (Sanger et al., Proc. Natl. Acad. Sci., USA, 74, 5463-5467 (1977)), etc. Furthermore, the polynucleotide sequence can also be easily determined by using a commercially available sequencing kit or the like.

[0168] 5. Foreign gene expression vector

[0169] As the exogenous gene expression vector of the present invention, there is provided a vector comprising the exogenous gene expression unit described in 2. above, wherein the exogenous gene expression unit described in 2. above comprises the promoter described in 1. above. The exogenous gene expression vector of the present invention may comprise one of the DNA elements described in 3. above, one of the DNA elements with more than two copies, or a combination of more than two of the DNA elements. When the exogenous gene is expressed in the host cell by the exogenous gene expression vector described above, the DNA element may be arranged immediately before or after the gene expression unit, or may be arranged at a position separated from the gene expression unit. In addition, one exogenous gene expression vector comprising a plurality of DNA elements may also be used. It should be noted that the orientation of the DNA element may be either forward or reverse relative to the gene expression unit.

[0170] Exogenous genes are not particularly limited, and examples thereof include reporter genes such as secretory alkaline phosphatase (SEAP), green fluorescent protein (GFP), and luciferase, various enzyme genes such as α-amylase gene and α-galactosidase gene, various interferon genes such as interferon α and interferon γ, various interleukin genes such as IL1 and IL2, various cytokine genes such as erythropoietin (EPO) gene and granulocyte colony stimulating factor (G-CSF) gene, growth factor genes, or genes encoding multimeric proteins, such as genes encoding heteromultimers of antibodies or antigen-binding fragments thereof, etc. These genes can be obtained by any method.

[0171] "Antigen-binding fragment of an antibody" refers to a partial fragment of an antibody having binding activity with an antigen, including Fab, F(ab')2, Fv, scFv, bispecific antibodies, linear antibodies, and multispecific antibodies formed by antibody fragments. In addition, a monovalent fragment of the variable region of an antibody formed by treating F(ab')2 under reducing conditions, i.e., Fab', is also included in the antigen-binding fragment of an antibody. However, as long as it has the ability to bind to an antigen, it is not limited to these molecules. In addition, these antigen-binding fragments include not only fragments formed by treating the full-length molecule of an antibody protein with a suitable enzyme, but also proteins produced in suitable host cells using genetically engineered antibody genes.

[0172] In addition, the exogenous gene expression vector of the present invention may contain a screening marker for screening transformants. For example, the screening of transformants can be performed by using a drug resistance marker that confers resistance to drugs such as cerulenin, aureobasidin, bleomycin, canavanine, cycloheximide, hygromycin, puromycin, blasticidin, tetracycline, kanamycin, ampicillin, and neomycin. In addition, the screening of transformants can also be performed by using a gene that confers resistance to solvents such as ethanol, osmotic pressure resistance to glycerol, salts, and metal ion resistance to copper as a marker.

[0173] The exogenous gene expression vector of the present invention can be a vector that is not incorporated into chromosomal DNA. Generally speaking, the exogenous gene expression vector is randomly incorporated into the chromosome after the gene is introduced into the host cell, but by using components derived from mammalian viruses such as simian virus 40 (SV40), papillomavirus (BPV, HPV), EBV, etc., it can be used as an episomal vector that can replicate autonomously in the introduced host cell. For example, vectors with sequences encoding the replication origin derived from SV40 and the SV40 large T antigen as a trans-acting factor, and vectors with sequences encoding oriP and EBNA-1 derived from EBV are widely used. As for the effect of the DNA element, it can show the activity of enhancing the expression of the exogenous gene, regardless of the type of vector or whether it is incorporated into the chromosome.

[0174] 6. Transformed Cells

[0175] The transformed cell of the present invention is a transformed cell obtained by introducing the foreign gene expression vector described in 5. above.

[0176] The host cell to be transformed is a eukaryotic cell, preferably a mammalian cell, and more preferably a cell derived from a human, mouse, rat, hamster, monkey or cow. Examples of mammalian cells include COS-1 cells, 293 cells, CHO cells (e.g., CHO-K1, CHO-O1, CHO DG44, CHO dhfr-, CHO-S, etc.), but are not limited to these.

[0177] In the present invention, any method may be used as long as the introduced gene can be stably present in the host and appropriately expressed. Commonly used methods include the calcium phosphate method (Ito et al., (1984) Agric. Biol. Chem., 48, 341), electroporation (Becker, DM et al., (1990) Methods. Enzymol., 194, 182-187), spheroplast method (Creggh et al., Mol. Cell. Biol., 5, 3376 (1985)), lithium acetate method (Itoh, H. (1983) J. Bacteriol. 153, 163-168), liposome transfection method, and the like.

[0178] In the transformed cells of the present invention, the foreign gene may be expressed transiently or stably, but is preferably expressed in a stable expression system.

[0179] Stable expression system refers to a method in which an expression vector is incorporated into a chromosome and expressed by calcium phosphate method, electroporation, liposome transfection, etc. The introduced gene can be maintained on the chromosome, and the expression of the introduced gene can be maintained for a long time for more than several weeks. In addition, if a selection marker is introduced into the plasmid, drug screening can be performed, and cells in which the introduced gene is maintained on the chromosome can be effectively selected.

[0180] 7. Methods for producing exogenous proteins

[0181] The production of the exogenous protein of the present invention can be carried out by the following method: the transformed cells described in the above item 6. are cultured by a known method, and the culture is collected and purified. "Culture" refers to any of cultured cells or cell fragments in addition to the culture supernatant. It should be noted that as the exogenous protein produced by the transformed cells described in the item 6., not only monomeric proteins but also multimeric proteins can be selected. In the case of producing a heterologous multimeric protein composed of a plurality of different subunits, it is necessary to introduce a plurality of genes encoding these subunits into the host cells described in the item 6. respectively.

[0182] The transformed cells can be cultured according to common methods for culturing host cells.

[0183] When the transformed cells are mammalian cells, for example, the culture is carried out at 37°C and 5% or 8% CO2 for about 24 to 1000 hours, and the culture can be carried out by batch culture, fed-batch culture, perfusion culture or continuous culture under static, shaking, stirring and ventilation. The culture is preferably fed-batch culture. The time for fed-batch culture of the transformed cells can be 3 days to 20 days, more preferably 5 days to 18 days, and particularly preferably 6 days to 15 days.

[0184] The expression product of the foreign protein gene can be confirmed from the aforementioned culture (culture solution) by SDS-PAGE, Western blot analysis, ELISA, or the like.

[0185] 8. Method for producing antibody protein

[0186] As a heterologous multimeric protein produced by the manufacturing method described in the project of the aforementioned 7., an antibody protein can be cited.Antibody protein is a tetrameric protein comprising 2 molecules of heavy chain polypeptide and 2 molecules of light chain polypeptide.Therefore, in order to obtain antibody protein in a form that maintains antigen binding ability, it is necessary to introduce both the genes of heavy chain and light chain into the transformed cells described in the project of the aforementioned 6. In this case, the gene expression units of heavy chain and light chain can be present on the same expression vector, or they can be present on different expression vectors.In the case of being present on the same expression vector, it can be present in the order of the gene expression unit of light chain and the gene expression unit of heavy chain from the reading direction of the gene, preferably in the order of DNA element, gene expression unit of light chain, and gene expression unit of heavy chain.It is further more preferred to include a screening marker after the DNA element, the gene expression unit of light chain, and the gene expression unit of heavy chain.

[0187] As antibodies produced in the present invention, antibodies produced by immunizing experimental animals such as rabbits, mice, and rats with desired antigens can be cited. In addition, as antibodies produced in the present invention, chimeric antibodies and humanized antibodies using the above antibodies as raw materials can also be cited. Moreover, human antibodies obtained by genetically modified animals or phage display technology are also antibodies produced in the present invention.

[0188] Antibody genes used for antibody production are not limited to those having a specific polynucleotide sequence as long as the combination of heavy chain polypeptide and light chain polypeptide transcribed and translated from the antibody gene retains the activity of binding to any antigen protein.

[0189] In addition, antibody genes do not necessarily need to encode full-length antibody molecules, and genes encoding antigen-binding fragments of antibodies can be used. Genes encoding these antigen-binding fragments can be obtained by genetically engineering genes encoding full-length antibody proteins.

[0190] 9. Methods for producing other exogenous proteins

[0191] In addition to the above-mentioned antibodies, the exogenous proteins to be used as the target of the production method of the present invention include various proteins derived from humans or non-human animals, antigen-binding fragments thereof, variants thereof, etc. Examples of such proteins include atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), C-type natriuretic peptide (C-type natriuretic peptide), and the like. peptide hormones such as (CNP), vasopressin, somatostatin, growth hormone (GH), insulin, oxytocin, ghrelin, leptin, adiponectin, renin, calcitonin, osteoprotegerin, insulin-like growth factor (IGF), interleukins, chemokines, interferons, tumor necrosis factors (TNFα / β and TNF superfamily, etc.), nerve growth factor (NGF), cell growth factors (EGF, FGF, PDGF, HGF, TGF, etc.), hematopoietic factors (CSF, G-CSF, erythropoietin, etc.), cytokines such as adipose factors, receptors such as TNF receptors, lysozymes, proteases (protease), proteinases (proteinase), enzymes such as peptidases, their functional fragments (fragments that retain part or all of the biological activity of the original protein), fusion proteins formed by containing these proteins, etc., but are not limited to these.

[0192] Example

[0193] Below, the present invention is specifically described by examples. However, these examples do not limit the technical scope of the present invention. The plasmid, restriction endonuclease, DNA modifying enzyme etc. used in the embodiments of the present invention are commercially available and can be used according to a conventional method. In addition, the operations used in cloning of DNA, determination of polynucleotide sequences, transformation of host cells, cultivation of transformed cells, collection of proteins from the obtained culture, purification etc. are also well known to those skilled in the art, or can be known through the literature.

[0194] (Example 1) Cloning of the promoter region of the Eno1 gene

[0195] As the promoter region of Eno1, the sequence from the nucleotide about 3.0 kbp upstream of the start codon sequence of the Eno1 gene to the nucleotide immediately before the nucleotide sequence corresponding to the start codon sequence was used with reference to the mRNA sequence registered as XM_027398299.1 in GenBank and the scaffold sequence of the Chinese hamster genome registered as NC_048595.1.

[0196] The promoter region of the Eno1 gene was amplified by PCR using the following primer set and PrimeSTAR Max DNA Polymerase (Takara Bio) using genomic DNA of CHO cells as a template, and purified using QIAquick PCR Purification kit (QIAGEN). The nucleotide sequence of the promoter region of the cloned Chinese hamster Eno1 gene is shown in SEQ ID NO: 1 in the sequence listing.

[0197] Primer set for Eno1 gene promoter

[0198] K24 (Fw): TTCGCGGCCGCGGCACGCAGCGCGCAGG (sequence number 8)

[0199] K25(Rev):

[0200] TTCACTAGTTGTCTGTAGGGGAAAAAAAAAAAAC (serial number 9)

[0201] (Example 2) Evaluation of the Chinese hamster-derived Eno1 gene promoter by fed-batch culture using antibody expression as an indicator

[0202] (2-1) Construction of antibody expression vector

[0203] As for the antibody expression vector, the DNA fragment amplified and purified in Example 1 was used to replace the nucleotide sequence corresponding to the Hspa5 gene promoter of the humanized antibody gene Y expression vector pDSLH3.1-Hspa5-Y described in Patent Document 4 with the nucleotide sequence of the Eno1 gene promoter derived from Chinese hamster, thereby constructing pDSLH3.1-Eno1-Y. A schematic diagram of the vector is shown in Figure 1 As a comparative object, pDSLH3.1-hEF1α-Y, a vector described in Patent Document 4, was used.

[0204] (2-2) Preparation of stable cell pool expressing humanized antibody Y

[0205] CHO-K1 cells (ATCC) were acclimated to be able to be cultured in suspension in serum-free medium to obtain host cell CHO-O1 cells. Using the gene introduction device Neon transfection system (Invitrogen), the antibody expression vector pDSLH3.1-Eno1-Y constructed in (2-1) or the pDSLH3.1-hEF1α-Y described in Patent Document 4 was introduced into CHO-O1 cells and cultured in a T-25 culture flask at 5% CO2 and 37°C. One day after gene introduction, Geneticin (Life Technologies Corporation) was added at a final concentration of 800μg / mL, and drug screening culture was performed for 1 week. Then, culture was performed in a 125mL Erlenmeyer flask at 5% CO2 and 37°C to produce a stable cell pool expressing humanized antibody Y (2 pools for each vector).

[0206] (2-3) Evaluation of Antibody Production Based on Fed-Batch Culture of Stable Cell Pools Expressing Humanized Antibody Y

[0207] The stable cell pool expressing humanized antibody Y prepared in (2-2) was used for 14 days of fed-batch culture in a 125 mL Erlenmeyer flask. The culture conditions were an initial seeding density of 0.3 × 10 6 cells / mL, culture medium volume 30mL, basal medium G13 (Fujifilm Wako Pure Chemical Industries, Ltd. custom-made medium), feed medium F13 (Fujifilm Wako Pure Chemical Industries, Ltd. custom-made medium). Feed medium is 3% (v / v) of the initial culture medium added every day from the 3rd day to the 13th day of culture. Samples were taken on the 7th, 10th, and 14th days to measure viable cell density, antibody production, etc.

[0208] The changes in the number of viable cells and the amount of antibody produced are shown in Figure 2-A , Figure 2-B The average antibody production of the two pools prepared for each vector was calculated and the antibody productivity was compared. The result showed that the antibody production using the Eno1 promoter on the 14th day of culture was 2.0 times that of the human EF1α promoter, which significantly exceeded the antibody production using the promoter that is currently frequently used.

[0209] (Example 3) Study on the promoter length of the Eno1 gene from Chinese hamster using the luminescence of transiently expressed luciferase as an indicator

[0210] (3-1) Construction of luciferase expression vector

[0211] The Eno1 promoter of each chain length was inserted into pGL4.10 (manufactured by Promega) to construct a vector expressing luciferase derived from firefly. The chain lengths studied were from the nucleotide immediately before the nucleotide sequence corresponding to the start codon sequence of the Eno1 gene to about 5.0 kbp upstream (SEQ ID NO: 10), to about 4.5 kbp upstream (SEQ ID NO: 11), to about 4.0 kbp upstream (SEQ ID NO: 4), to about 3.5 kbp upstream (SEQ ID NO: 12), to about 3.0 kbp upstream (SEQ ID NO: 1), to about 2.8 kbp upstream (SEQ ID NO: 3), to about 2.7 kbp upstream (SEQ ID NO: 13), to about 2.6 kbp upstream (SEQ ID NO: 14), and to about 2.5 kbp upstream (SEQ ID NO: 15).

[0212] (3-2) Evaluation of luciferase luminescence based on transient expression

[0213] Using Lipofectamin2000 CD (manufactured by Thermo Fisher Scientific), the vector expressing luciferase from firefly (Firefly) constructed in (3-1) and the control vector pGL4.74 expressing luciferase from Renilla (Renilla) were simultaneously introduced into CHO-O1 cells. After gene introduction, the cells were centrifuged (1000rpm, 3 minutes) after 24 hours, recovered into a 1.5mL tube, and washed with PBS buffer. Then, the luminescence of luciferase was measured using Dual-Luciferase Reporter Assay System (manufactured by Promega). It should be noted that gene introduction was implemented with N=2 for each promoter length.

[0214] The value obtained by dividing the luminescence amount of the firefly-derived luciferase on pGL4.10 by the luminescence amount of the Renilla-derived luciferase on pGL4.74 was taken as the promoter activity ( Figure 3). In addition, the average value calculated from the promoter activity obtained with N=2 is shown in Table 1. As a result, when the region from the nucleotide immediately before the nucleotide sequence corresponding to the start codon sequence of the Eno1 gene derived from the Chinese hamster to about 5.0 kbp upstream of the start codon sequence (sequence number 10), to about 4.5 kbp upstream (sequence number 11), to about 4.0 kbp upstream (sequence number 4), to about 3.5 kbp upstream (sequence number 12) was used, more than 80% of the promoter activity in the case of using the region to about 3.0 kbp upstream (sequence number 1) was obtained. In addition, when the region from the nucleotide immediately before the nucleotide sequence corresponding to the start codon sequence to 2.8 kbp upstream of the start codon sequence (sequence number 3) was used, almost the same promoter activity as the case of using the region to about 3.0 kbp upstream (sequence number 1) was obtained. When using the region from the nucleotide immediately before the nucleotide sequence corresponding to the start codon sequence to about 2.7 kbp upstream of the start codon sequence (sequence number 13) and to about 2.6 kbp upstream (sequence number 14), a promoter activity of about 50% was obtained compared with the case of using the region to about 3.0 kbp upstream (sequence number 1). In addition, when using the region from the nucleotide immediately before the nucleotide sequence corresponding to the start codon sequence to about 2.5 kbp upstream of the start codon sequence (sequence number 15), a promoter activity of about 15% was obtained compared with the case of using the region to about 3.0 kbp upstream (sequence number 1). According to the above confirmation, the transcriptional activity of the promoter of the Eno1 gene derived from the Chinese hamster is significantly higher in the region of length from the nucleotide immediately before the nucleotide sequence corresponding to the start codon sequence to about 2.8 kbp or more upstream of the start codon sequence.

[0215] In addition, between sequence number 3 (Eno1 2.8k) and sequence number 13 (Eno1 2.7k), the transcription activity of the promoter of sequence number 3 (Eno1 2.8k) was significantly superior. Therefore, it is believed that when the promoter has sequence number 18 (the difference sequence (100 bp) between sequence number 3 (Eno1 2.8k) and sequence number 13 (Eno1 2.7k)), the transcription activity is particularly improved.

[0216] [Table 1]

[0217]

[0218] (Example 4) Evaluation of the mouse-derived Eno1 gene promoter using antibody expression as an indicator by fed-batch culture

[0219] (4-1) Construction of antibody expression vector

[0220] The promoters of the antibody H chain and L chain genes in the humanized antibody gene Y expression vector pDSLH3.1-hEF1α-Y were replaced with the mouse Eno1 promoter to construct pDSLH3.1-mEno1-Y, pDSLH3.1-mEno1-3.5-Y, and pDSLH3.1-mEno1-4.0-Y. The mouse-derived Eno1 gene promoter used a region from the nucleotide immediately before the nucleotide sequence corresponding to the start codon sequence of Eno1 to about 3.0 kbp upstream of the start codon sequence (SEQ ID NO: 2), a region to about 3.5 kbp upstream (SEQ ID NO: 17), or a region to about 4.0 kbp upstream (SEQ ID NO: 16).

[0221] Similarly, the region from the nucleotide immediately preceding the nucleotide sequence corresponding to the start codon sequence of Eno1 derived from the Chinese hamster Eno1 gene promoter to about 4.0 kbp upstream of the start codon sequence (sequence number 4), the region to about 3.5 kbp upstream (sequence number 12), and the region to about 2.8 kbp upstream (sequence number 3) were used as Eno1 gene promoters to construct pDSLH3.1-Eno1-4.0-Y, pDSLH3.1-Eno1-3.5-Y, and pDSLH3.1-Eno1-2.8-Y.

[0222] (4-2) Preparation of stable cell pool expressing humanized antibody Y

[0223] pDSLH3.1-hEF1α-Y (Patent Document 4), DSLH3.1-Eno1-Y constructed in (2-1), pDSLH3.1-mEno1-Y constructed in (4-1), pDSLH3.1-mEno1-3.5-Y, pDSLH3.1-mEno1-4.0-Y, pDSLH3.1-Eno1-2.8-Y, pDSLH3.1-Eno1-3.5-Y and pDSLH3.1-Eno1-4.0-Y were transfected into CHO-O1 cells by the method described in (2-2), cultured for drug screening, and humanized antibody Y-expressing stable cell pools were prepared (two pools for each vector).

[0224] (4-3) Evaluation of Antibody Production Based on Fed-Batch Culture of Stable Cell Pools Expressing Humanized Antibody Y

[0225] The stable cell pool expressing humanized antibody Y prepared in (4-2) was used for fed-batch culture in a 125 mL Erlenmeyer flask. G13 was used as the basal medium and F13 was used as the feed medium.

[0226] The changes in the number of viable cells and the amount of antibody produced are shown in Figure 4-A , Figure 4-B The average antibody production of the two pools prepared for each vector was calculated, and the antibody productivity was compared. As a result, the antibody production at the 14th day of culture was 1.3 times, 1.8 times, and 1.9 times higher than that of the human EF1α promoter (hEF1α) using the mouse-derived Eno1 gene promoter 3.0kbp (mEno1 3k), 3.5kbp (mEno13.5k), and 4.0kbp (mEno1 4k), respectively, which greatly exceeded the antibody production using the currently widely used promoter. It can be seen that the mouse-derived Eno1 gene promoter also has the same promoter ability as the Chinese hamster-derived Eno1 gene promoter.

[0227] Using the Eno1 gene promoter 2.8kbp (Eno1 2.8k), 3.0kbp (Eno1 3k), 3.5kbp (Eno1 3.5k) and 4.0kbp (Eno1 4k) from Chinese hamster, the values ​​reached 2.7 times, 2.0 times, 2.8 times and 3.1 times that of the human EF1α promoter respectively (at the 14th day of culture), significantly exceeding the antibody production using the currently widely used promoter.

[0228] When the antibody productivity of the mouse-derived Eno1 gene promoter and the Chinese hamster-derived Eno1 gene promoter was compared, it was found that the Chinese hamster-derived Eno1 gene promoter was superior.

[0229] Furthermore, the amount of antibody produced per cell per day (Qp) was calculated according to the following formula.

[0230] Qp = [Antibody production on day 10] ÷ [Cumulative viable cell density on day 10]

[0231] (The integrated value of the time-dependent change in viable cell density calculated using the viable cell densities on days 0, 7, and 10 is referred to as the "cumulative viable cell density on day 10")

[0232] The promoters of the Eno1 gene from Chinese hamster, 2.8 kbp (Eno1 2.8k), 3.0 kbp (Eno1 3k), 3.5 kbp (Eno1 3.5k) and 4.0 kbp (Eno1 4k), were 2.7 times, 2.3 times, 3.0 times and 3.1 times that of the human EF1α promoter, respectively.

[0233] The promoters of the mouse Eno1 gene, 3 kbp (mEno1 3k), 3.5 kbp (mEno1 3.5k), and 4 k (mEno1 4k), were 1.9 times, 2.2 times, and 2.4 times higher than those of the human EF1α promoter, respectively.

[0234] When comparing the amount of antibody produced per cell (Qp), it was found that the Chinese hamster-derived Eno1 gene promoter was superior to the mouse-derived Eno1 gene promoter.

[0235] (Example 5) Study on the effect of the combination of Eno1 gene promoter derived from various biological species and A7 using the antibody expression level in fed-batch culture as an indicator

[0236] (5-1) Construction of antibody expression vector

[0237] Using pDSLH3.1-Eno1-Y constructed in (2-1), pDSLH3.1-Eno1-3.5-Y, pDSLH3.1-Eno1-2.8-Y, pDSLH3.1-mEno1-Y, pDSLH3.1-mEno1-3.5-Y, pDSLH3.1-mEno1-4.0-Y and pDSLH3.1-Eno1-4.0-Y constructed in (4-1) as parent vectors, DNA element A7 (sequence number 6) was inserted upstream of their expression cassettes by the same method as in Patent Document 5 to construct an antibody expression vector.

[0238] (5-2) Preparation of stable cell pool expressing humanized antibody Y

[0239] The parent vector and antibody expression vector A7 were transfected into CHO-01 cells by the method described in (2-2), and cultured for drug screening to prepare humanized antibody Y-expressing stable cell pools (2 pools for each vector).

[0240] (5-3) Evaluation of Antibody Production Based on Fed-Batch Culture of Stable Cell Pools Expressing Humanized Antibody Y

[0241] The humanized antibody Y expression stable cell pool prepared in (5-2) was used for fed-batch culture in a 125 mL volumetric conical flask. G13 was used as the basal medium and F13 was used as the feed medium. The changes in the number of viable cells and the antibody production are shown in Figures 5A and 5B, respectively. The average value of the antibody production of the two pools prepared for each vector was calculated, and the antibody productivity was compared. The antibody production based on the antibody expression vector containing A7 at the 14th day of culture showed a value of 1.7 to 5.4 times that of the antibody expression vector not containing A7. It can be seen that when the DNA element A7 is used in combination with the Eno1 gene promoter derived from either Chinese hamster or mouse, the antibody productivity is greatly improved.

[0242] Sequence Listing Free Text

[0243] SEQ ID NO: 1: The promoter of the Eno1 gene derived from Chinese hamster consists of a nucleotide sequence from the nucleotide about 3.0 kbp upstream of the start codon of the Eno1 gene to the nucleotide immediately before the nucleotide sequence corresponding to the start codon

[0244] SEQ ID NO: 2: The promoter of the mouse Eno1 gene consists of a nucleotide sequence from the nucleotide about 3.0 kbp upstream of the start codon of the Eno1 gene to the nucleotide immediately before the nucleotide sequence corresponding to the start codon.

[0245] SEQ ID NO: 3: The promoter of the Eno1 gene derived from Chinese hamster consists of a nucleotide sequence from the nucleotide about 2.8 kbp upstream of the start codon of the Eno1 gene to the nucleotide immediately before the nucleotide sequence corresponding to the start codon

[0246] SEQ ID NO: 4: The promoter of the Eno1 gene derived from Chinese hamster comprises a nucleotide sequence consisting of a nucleotide approximately 4.0 kbp upstream of the start codon of the Eno1 gene to the nucleotide immediately before the nucleotide sequence corresponding to the start codon

[0247] SEQ ID NO: 5: Nucleotide sequence of DNA element A2

[0248] SEQ ID NO: 6: Nucleotide sequence of DNA element A7

[0249] SEQ ID NO: 7: Nucleotide sequence of DNA element A18

[0250] SEQ ID NO: 8: Primer K24 of Eno1 gene promoter

[0251] SEQ ID NO: 9: Primer K25 for Eno1 gene promoter

[0252] SEQ ID NO: 10: The promoter of the Eno1 gene derived from Chinese hamster comprises a nucleotide sequence consisting of a nucleotide approximately 5.0 kbp upstream of the start codon of the Eno1 gene to the nucleotide immediately before the nucleotide sequence corresponding to the start codon

[0253] SEQ ID NO: 11: The promoter of the Eno1 gene derived from Chinese hamster comprises a nucleotide sequence consisting of a nucleotide approximately 4.5 kbp upstream of the start codon of the Eno1 gene to the nucleotide immediately before the nucleotide sequence corresponding to the start codon

[0254] SEQ ID NO: 12: The promoter of the Eno1 gene derived from Chinese hamster comprises a nucleotide sequence consisting of a nucleotide approximately 3.5 kbp upstream of the start codon of the Eno1 gene to the nucleotide immediately before the nucleotide sequence corresponding to the start codon

[0255] SEQ ID NO: 13: The promoter of the Eno1 gene derived from Chinese hamster comprises a nucleotide sequence consisting of a nucleotide approximately 2.7 kbp upstream of the start codon of the Eno1 gene to the nucleotide immediately before the nucleotide sequence corresponding to the start codon

[0256] SEQ ID NO: 14: The promoter of the Eno1 gene derived from Chinese hamster comprises a nucleotide sequence consisting of a nucleotide approximately 2.6 kbp upstream of the start codon of the Eno1 gene to the nucleotide immediately before the nucleotide sequence corresponding to the start codon

[0257] SEQ ID NO: 15: The promoter of the Eno1 gene derived from Chinese hamster comprises a nucleotide sequence consisting of a nucleotide approximately 2.5 kbp upstream of the start codon of the Eno1 gene to the nucleotide immediately before the nucleotide sequence corresponding to the start codon

[0258] SEQ ID NO: 16: The promoter of the mouse Eno1 gene consists of a nucleotide sequence from the nucleotide approximately 4.0 kbp upstream of the start codon of the Eno1 gene to the nucleotide immediately before the nucleotide sequence corresponding to the start codon.

[0259] SEQ ID NO: 17: The promoter of the mouse Eno1 gene consists of a nucleotide sequence from the nucleotide approximately 3.5 kbp upstream of the start codon of the Eno1 gene to the nucleotide immediately before the nucleotide sequence corresponding to the start codon

[0260] Sequence number 18: The difference between sequence number 3 (Eno1 2.8k) and sequence number 13 (Eno1 2.7k)

Claims

1. A polynucleotide which is a promoter of a gene derived from Chinese hamster, The polynucleotide is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13 and SEQ ID NO: 14, or, The polynucleotide comprises a nucleotide sequence having at least 85% sequence identity with these sequences or a partial sequence of the nucleotide sequence.

2. The polynucleotide according to claim 1, which is selected from SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 12, or, The polynucleotide comprises a nucleotide sequence having at least 85% sequence identity with these sequences or a partial sequence of the nucleotide sequence.

3. The polynucleotide according to claim 1, comprising a nucleotide sequence having a sequence identity of at least 99% with the nucleotide sequence of SEQ ID NO:

1. 4 . The polynucleotide according to claim 1 , comprising a nucleotide sequence having a sequence identity of at least 99% with the nucleotide sequence of SEQ ID NO:

3. 5 . The polynucleotide according to claim 1 , comprising a nucleotide sequence having at least 99% sequence identity with the nucleotide sequence of SEQ ID NO:

4. The polynucleotide according to claim 1 , comprising a nucleotide sequence having a sequence identity of at least 99% with the nucleotide sequence of SEQ ID NO:

10.

7. The polynucleotide according to claim 1, comprising a nucleotide sequence having a sequence identity of at least 99% with the nucleotide sequence of SEQ ID NO:

11.

8. The polynucleotide according to claim 1, comprising a nucleotide sequence having a sequence identity of at least 99% with the nucleotide sequence of SEQ ID NO:

12. 9 . The polynucleotide according to claim 1 , comprising a nucleotide sequence having a sequence identity of at least 99% with the nucleotide sequence of SEQ ID NO:

13. 10 . The polynucleotide according to claim 1 , comprising a nucleotide sequence having a sequence identity of at least 99% with the nucleotide sequence of SEQ ID NO:

14.

11. A polynucleotide which is a promoter of a gene derived from a mouse, The polynucleotide is selected from SEQ ID NO: 2, SEQ ID NO: 17 and SEQ ID NO: 16, or, The polynucleotide comprises a nucleotide sequence having at least 85% sequence identity with these sequences or a partial sequence of the nucleotide sequence. 12 . The polynucleotide according to claim 11 , comprising a nucleotide sequence having a sequence identity of at least 99% with the nucleotide sequence of SEQ ID NO:

2.

13. The polynucleotide according to claim 11, comprising a nucleotide sequence having a sequence identity of at least 99% with the nucleotide sequence of SEQ ID NO:

17.

14. The polynucleotide according to claim 11, comprising a nucleotide sequence having a sequence identity of at least 99% with the nucleotide sequence of SEQ ID NO:

16.

15. A polynucleotide having promoter activity, wherein the polynucleotide comprises a nucleotide sequence having a sequence identity of 90% or more to the nucleotide sequence of sequence number 1, sequence number 3, sequence number 4, sequence number 10, sequence number 11, sequence number 12, sequence number 13, sequence number 14, sequence number 2, sequence number 17 or sequence number 16 described in claim 1 or 11, or a partial sequence of the nucleotide sequence.

16. A polynucleotide having promoter activity, wherein the polynucleotide comprises a nucleotide sequence having a sequence identity of 95% or more to the nucleotide sequence of sequence number 1, sequence number 3, sequence number 4, sequence number 10, sequence number 11, sequence number 12, sequence number 13, sequence number 14, sequence number 2, sequence number 17 or sequence number 16 described in claim 1 or 11, or a partial sequence of the nucleotide sequence.

17. A polynucleotide having promoter activity, which is a polynucleotide that hybridizes under strict conditions with a polynucleotide comprising a nucleotide sequence complementary to the nucleotide sequence of sequence number 1, sequence number 3, sequence number 4, sequence number 10, sequence number 11, sequence number 12, sequence number 13, sequence number 14, sequence number 2, sequence number 17 or sequence number 16 recorded in claim 1 or 11.

18. The polynucleotide according to claim 17, which is a promoter of a gene derived from Chinese hamster, and the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 18 or a nucleotide sequence having a sequence identity of at least 85% with the sequence.

19. A foreign gene expression unit comprising a foreign gene and the polynucleotide according to any one of claims 1 to 18.

20. The exogenous gene expression unit according to claim 19, wherein Foreign genes are genes that encode proteins.

21. The exogenous gene expression unit according to claim 20, wherein: Foreign genes are genes encoding heteromultimeric proteins.

22. The exogenous gene expression unit according to claim 21, wherein The foreign gene is a gene encoding an antibody or an antigen-binding fragment thereof.

23. A foreign gene expression vector comprising the foreign gene expression unit according to any one of claims 19 to 22.

24. An exogenous gene expression vector comprising: The exogenous gene expression unit according to any one of claims 19 to 22; and A polynucleotide selected from any one or more of the following (a) to (e), (a) the nucleotide sequence of SEQ ID NO: 5 or a partial sequence thereof; (b) the nucleotide sequence of SEQ ID NO: 6 or a partial sequence thereof; (c) the nucleotide sequence of SEQ ID NO: 7 or a partial sequence thereof; (d) a polynucleotide comprising a nucleotide sequence having a sequence identity of 80% or more to the nucleotide sequence of SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 7, or a partial sequence of the nucleotide sequence, wherein the polynucleotide has an activity of enhancing the expression of a foreign gene; (e) A polynucleotide comprising a nucleotide sequence having a sequence identity of 85% or more to the nucleotide sequence of SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 7, or a partial sequence of the nucleotide sequence, wherein the polynucleotide has an activity of enhancing the expression of a foreign gene.

25. A transformed cell into which the foreign gene expression vector according to claim 23 or 24 is introduced. The transformed cell according to claim 25 , which is a cultured cell derived from a mammal.

27. The transformed cell according to claim 26, which is a COS-1 cell, a 293 cell or a CHO cell.

28. A method for producing a protein, characterized in that: The transformed cell according to any one of claims 25 to 27 is cultured, and a protein derived from a foreign gene is obtained from the culture.

29. The manufacturing method according to claim 28, wherein: The protein derived from the foreign gene is a monomeric protein or a polymeric protein.

30. The manufacturing method according to claim 29, wherein: Multimeric proteins are heteromultimeric proteins.

31. The manufacturing method according to claim 30, wherein: The heteromultimeric protein is an antibody protein.

32. Use of the polynucleotide according to any one of claims 1 to 18 for expressing a foreign gene in a transformed cell.

33. Use of the foreign gene expression vector according to claim 23 or 24 for expressing foreign genes in transformed cells.